Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT03429933 Completed - Clinical trials for Healthy Participants

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Start date: February 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate experimental medication BMS-986278 given to healthy participants.

NCT ID: NCT03424577 Completed - Clinical trials for Healthy Participants

A Study to Evaluate the Food-Effect of H3B-6527

Start date: December 27, 2017
Phase: Phase 1
Study type: Interventional

This study will be conducted to determine the effect of food on the relative bioavailability of H3B-6527 following administration of a H3B-6527 capsule with and without a meal.

NCT ID: NCT03413592 Completed - Clinical trials for Healthy Participants

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the intra-individual difference of the SDLP values in driving simulator.

NCT ID: NCT03399734 Completed - Clinical trials for Healthy Participants

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Start date: December 18, 2017
Phase: Phase 1
Study type: Interventional

This study will be conducted to demonstrate the bioequivalence between a single 4 milligram (mg) dose of fine granules of perampanel and a single 4 mg tablet of perampanel.

NCT ID: NCT03376997 Completed - Clinical trials for Healthy Participants

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Start date: November 8, 2017
Phase: Phase 1
Study type: Interventional

This study will be conducted to evaluate the bioavailability of a single 12 milligram (mg) dose of perampanel intravenous infusions of different durations relative to a single 12 mg dose of perampanel oral tablet in healthy participants.

NCT ID: NCT03374228 Completed - Clinical trials for Healthy Participants

A Study to Evaluate the Bioavailability of BMS-986205

Start date: January 4, 2018
Phase: Phase 1
Study type: Interventional

Assess the absolute bioavailability of a tablet formulation of BMS-986205 following simultaneous oral administration of BMS-986205 and intravenous infusion of [13C]BMS-986205 solution for intravenous administration in healthy participants.

NCT ID: NCT03343626 Completed - Clinical trials for Healthy Participants

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

Start date: November 13, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to describe the safety, tolerability and immunogenicity of two doses of purified inactivated Zika virus vaccine (PIZV) given 28 days apart. Three different vaccine doses containing different protein concentrations (2, 5 or 10 microgram [mcg]) each, will be given as 2 dose schedule to flavivirus naive and primed healthy adults. Participants will be followed for 7 days post each dose for tolerability and up to 6 months post dose 2 for safety. Immunogenicity assessment will be performed at 28 days post each dose and 6 months post dose 2. In addition, the selected dose group and control group will be followed till 24 months post dose 2 for safety and persistence of immunity.

NCT ID: NCT03278080 Completed - Clinical trials for Healthy Participants

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1

Start date: September 22, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to set an optimal measurement time for assessing driving ability in a driving simulator in healthy volunteers.

NCT ID: NCT03236844 Completed - Clinical trials for Healthy Participants

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administration.

NCT ID: NCT03229434 Completed - Clinical trials for Healthy Participants

Mountain Hiking & Environmental Influences

Start date: October 29, 2017
Phase: N/A
Study type: Interventional

In a randomized crossover design, approximately 50 healthy participants will be randomly exposed to outdoor mountain hiking (approximately 6 hours each) in two different areas: an anthropogenically influenced area and in a widely pristine area.